Predicting Outcomes With First-Line Antiangiogenics Plus Chemotherapy in mCRC

Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite stable metastatic colorectal cancer without liver metastases.

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Patients with BRAF V600E-mutant metastatic colorectal cancer experienced poor clinical outcomes with systemic therapy, according to real-world data.

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Early palliative care reduces invasive interventions and enhances comfort at EOL for CRC patients, according to real-world study results.

Adagrasib plus cetuximab sustained clinical efficacy in KRAS G12C–mutant unresectable or metastatic colorectal cancer with longer follow-up, according to the KRYSTAL-1 trial.